
RA Capital, InCube lead $30m series-B for WhiteSwell
RA Capital Management has led a $30m series-B funding round for Irish biotechnology company WhiteSwell alongside an InCube Ventures syndicate.
The fresh capital will fund product development and medical studies of the company's treatment for acute decompensated heart failure (ADHF).
As part of the deal, WhiteSwell has appointed former Neuravi CEO Eamon Brady and former Neuravi CFO Seán Mac Réamoinn in the same roles.
Company
Founded in Israel in 2014 and now headquartered in Galway, WhiteSwell is developing a minimally invasive catheter-based treatment for ADHF. The treatment is intended to remove excess interstitial fluid in patients with ADHF more efficiently by bolstering the natural fluid removal process of the lymphatic system.
People
RA Capital – Andrew Levin (managing director).
InCube Ventures – Andrew Farquharson (co-founder, managing director).
WhiteSwell – Yaacov Nitzan (founder, chief technology officer).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater